Core Insights - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024 [1] - The average annual salary of CFOs in the biopharmaceutical sector is 1.0042 million yuan [1] - The age distribution shows that CFOs aged 40-50 constitute 54% of the market, while those over 50 account for 38% [1] Salary Distribution - The salary distribution among CFOs is as follows: below 500,000 yuan (13%), 500,000-1,000,000 yuan (46%), 1,000,000-2,000,000 yuan (33%), and above 2,000,000 yuan (8%) [1] - The top five highest-paid CFOs are from Kanghong Pharmaceutical, Junshi Biosciences-U, Shenzhou Cell, Tebao Biologics, and Aopumai, with salaries of 3 million, 2.0602 million, 1.4297 million, 1 million, and 1 million yuan respectively [1] Salary Changes - The largest salary decrease was observed for Xu Baohong from Junshi Biosciences-U, with a year-on-year decline of 24.66% [1] - The largest salary increase was for Liu Liwen from Zhixiang Jintai-U, with a year-on-year increase of 35.91% [1]

Group 1 - The stock of Junshi Biosciences (01877) experienced a significant increase, rising over 11% recently, following a previous surge of over 33% on August 5 [1] - As of the latest report, the stock is up 8.14%, trading at HKD 29.5, with a trading volume of HKD 531 million [1] - Junshi Biosciences completed a placement of 41 million new shares on June 20, raising a net amount of approximately HKD 1.026 billion, with 70% allocated for innovative drug research and 30% for general corporate purposes [1] Group 2 - The company is focusing on the development of innovative drugs, including PD-1/VEGF bispecific antibodies, EGFR/HER3 ADC, and PD-1/IL-2 fusion proteins [1] - According to Fangzheng Securities, JJS207 has significant business development (BD) potential, as international pharmaceutical companies are interested in PD-1/VEGF products [1] - Open Source Securities noted that by May 2025, only Pfizer and Merck have entered this market segment among multinational corporations (MNCs), indicating potential for other early-stage PD-(L)1/VEGF bispecific antibodies to expand internationally as data matures [1]

Group 1 - Junshi Biosciences (01877) experienced a significant stock price increase, rising over 11% at one point, following a previous surge of over 33% on August 5 [1] - As of the report, the stock is up 8.14%, trading at HKD 29.5, with a trading volume of HKD 531 million [1] - The company completed a placement of 41 million new shares on June 20, raising approximately HKD 1.026 billion, with 70% of the funds allocated for innovative drug research and 30% for general corporate purposes [1] Group 2 - Junshi Biosciences plans to use the raised funds for the development of various drug candidates, including PD-1/VEGF bispecific antibodies, EGFR/HER3 ADC, and PD-1/IL-2 fusion proteins [1] - According to a report from Founder Securities, JJS207 has significant business development (BD) potential, as international pharmaceutical companies are interested in PD-1/VEGF products [1] - Open Source Securities noted that by May 2025, only Pfizer and Merck have entered this market segment among multinational corporations, suggesting that other early-stage PD-(L)1/VEGF bispecific antibodies from China may have opportunities for international business development as data matures [1]

Core Viewpoint - The innovative drug concept stocks are experiencing a rebound, with companies such as Northland Pharmaceutical, Lianhuan Pharmaceutical, Lepu Medical, Junshi Biosciences, Jingxin Pharmaceutical, and Guangsheng Pharmaceutical seeing increases of over 5% [1] Group 1 - Northland Pharmaceutical has shown significant growth in stock price [1] - Lianhuan Pharmaceutical is among the companies that have risen over 5% [1] - Lepu Medical has also reported a stock increase exceeding 5% [1] Group 2 - Junshi Biosciences is part of the group of innovative drug stocks that have rebounded [1] - Jingxin Pharmaceutical has experienced a notable rise in its stock value [1] - Guangsheng Pharmaceutical has joined the trend with a stock increase of over 5% [1]

FF301 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | 1 RMB | | 260,295,700 | | 2. 股份分類 | 普通股 | 股份類別 ...

Core Viewpoint - Junshi Biosciences is positioned as a leading innovative pharmaceutical company in China, focusing on the development and commercialization of first-in-class and best-in-class drugs, with a comprehensive industry chain from drug discovery to large-scale production and global clinical research [2][3]. Company Overview - Junshi Biosciences was established on December 27, 2012, and went public on July 15, 2020. The company is headquartered in Shanghai and specializes in the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [7]. - The main revenue sources for the company include drug sales (84.18%), technology licensing and royalties (12.08%), and other income (3.73%) [7]. Recent Developments - On October 27, 2023, Junshi Biosciences announced a collaboration with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Advanced Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [3]. - The company’s subsidiary, JunTuo Biotech, is involved in the development of vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [3]. Financial Performance - For the period from January to March 2025, Junshi Biosciences reported a revenue of 5.01 billion yuan, representing a year-on-year growth of 31.46%. However, the net profit attributable to the parent company was -2.35 billion yuan, showing a year-on-year increase of 17.01% [8]. Market Activity - On August 6, 2023, Junshi Biosciences' stock rose by 4.61%, with a trading volume of 1.663 billion yuan and a turnover rate of 5.09%, bringing the total market capitalization to 42.382 billion yuan [1].

本文源自：金融界AI电报 昨日暴涨近34%的君实生物(1877.HK)今日回调，盘中跌12%报28.32港元。 ...

北京商报讯（记者 丁宁）8月6日，创新药概念股再度走强，其中，君实生物（688180）涨超10%，泓 博医药、康弘药业、悦康药业等个股跟涨。 ...

上海君实生物医药科技股份有限公司主要业务是发现、开发和商业化创新疗法，特别是在肿瘤免疫疗 法、自身免疫系统疾病、慢性代谢类疾病、神经系统疾病、感染类疾病等治疗方面。公司拥有卓越的创 新药物发现能力、先进的生物技术研发、全产业链大规模生产技术和极具市场潜力的在研药品组合。 8月6日，君实生物(01877)盘中下跌4.91%，截至09:45，报30.6元/股，成交3.36亿元。 本文源自：金融界 作者：行情君 截至2025年一季报，君实生物营业总收入5.01亿元、净利润-2.35亿元。 ...